Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
In this episode: Survodutide obesity and liver fat reduction data Mazdutide Phase 3 obesity and diabetes results UBT251 triple agonist weight loss data Berobenatide (MET-097) long-acting GLP-1 updates CagriSema diabetes and obesity trial results Zenagamtide (Amycretin) injectable and oral development Petrelintide amylin agonist info Future GLP-1, GIP, glucagon, and amylin therapies The future of obesity medicine is no longer just about who produces the most weight loss
BPC-157 is not approved by Health Canada or the FDA for therapeutic use
Some people linked these changes to weight loss, improved body image, better metabolic health, and mental well-being, while others suggested age or underlying health conditions may also play a role
Novo completes $16.5bn takeover of Catalent
The semaglutide injection has been priced at 2,200 per week for the 0.25 mg dose
Microdiscectomy removes the portion of disc material compressing the nervethe most common surgery for disc-related sciatica
US$ 25.22
US$ 27.04
US$ 28.60
US$ 28.31
US$ 21.68
US$ 23.22
US$ 25.52
